ADMA Biologics, Inc. (ADMA)
$
14.54
-0.20 (-1.38%)
Key metrics
Financial statements
Free cash flow per share
0.2737
Market cap
3.5 Billion
Price to sales ratio
7.3173
Debt to equity
0.2104
Current ratio
5.3317
Income quality
0.3672
Average inventory
181.8 Million
ROE
0.6178
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics to address immune deficiencies and infectious diseases both in the United States and internationally. The company recorded a notable revenue of $426,454,000.00 showcasing its steady growth. Among its key offerings are BIVIGAM, an intravenous immune globulin (IVIG) product for treating primary humoral immunodeficiency (PI), ASCENIV, another IVIG product designed for the same condition, and Nabi-HB, indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen along with other potential exposures to Hepatitis B. Additionally, ADMA Biologics is developing a pipeline of plasma-derived therapeutics, including innovative products aimed at the treatment and prevention of S. pneumonia infections for immunoglobulin. The cost of revenue for the company is $206,901,000.00 showcasing its production and operational expenses, while the total costs and expenses for the company are $282,838,000.00 reflecting its overall spending. The company's stock is identified with the symbol 'ADMA' in the market, and the weighted average number of diluted shares outstanding is 243,342,000.00 indicating potential dilution effects. Moreover, the stock is affordable at $15.91 making it suitable for budget-conscious investors seeking opportunities. With a high average trading volume of 3,258,725.00 the stock demonstrates strong liquidity, which is an advantageous factor for traders. With a mid-range market capitalization of $3,469,690,654.00 the company is a steady performer in the biopharmaceutical realm. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth within the Healthcare sector. This dual focus on patient needs and robust market engagement aligns ADMA Biologics as an important entity shaping the future of plasma-derived therapeutics.
Is ADMA Biologics, Inc. (ADMA) a good investment?
Investing in ADMA Biologics, Inc. (ADMA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is ADMA Biologics, Inc. (ADMA)'s stock forecast?
Analysts predict ADMA Biologics, Inc. stock to fluctuate between $13.50 (low) and $25.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is ADMA Biologics, Inc.'s market capitalization?
As of 2025-10-10, ADMA Biologics, Inc.'s market cap is $3,469,690,654, based on 238,630,719 outstanding shares.
How does ADMA Biologics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., ADMA Biologics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy ADMA Biologics, Inc. (ADMA) stock?
To buy ADMA Biologics, Inc. (ADMA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ADMA. Place an order (Market, Limit, etc.).
What is the best time to invest in ADMA Biologics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did ADMA Biologics, Inc. perform in the last earnings report?
Revenue: $426,454,000 | EPS: $0.85 | Growth: -753.85%.
Where can I find ADMA Biologics, Inc.'s investor relations reports?
Visit https://www.admabiologics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for ADMA Biologics, Inc.?
You can explore historical data from here
What is the all-time high and low for ADMA Biologics, Inc. stock?
All-time high: $25.67 (2025-04-28) | All-time low: $1.01 (2021-10-21).
What are the key trends affecting ADMA Biologics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
zacks.com
Adma Biologics (ADMA) concluded the recent trading session at $15.05, signifying a +2.66% move from its prior day's close.
zacks.com
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
zacks.com
In the latest trading session, Adma Biologics (ADMA) closed at $15.32, marking a -2.17% move from the previous day.
zacks.com
In the latest trading session, Adma Biologics (ADMA) closed at $15.91, marking a -1.55% move from the previous day.
zacks.com
Adma Biologics (ADMA) closed the most recent trading day at $15.3, moving 5.03% from the previous trading session.
zacks.com
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
seekingalpha.com
ADMA Biologics' earnings are surging due to higher plasma yield and a profitable shift toward premium IG brands, boosting margins. FDA approval of yield-enhancement technology increases finished IG output by 20%, driving efficiency and supporting ongoing revenue and margin growth. Expanded plasma sourcing and improved logistics de-risk supply, supporting long-term growth and simplifying distribution for key products.
seekingalpha.com
ADMA's growth remains centered on Asceniv, Bivigam, and NABI-HB. These are its main value drivers today. ADMA Biologics' recent Q2 report showed that the company is working on enhancing its plasma yields by over 20% in IG output. This should help them with margin expansion beginning in 2026. ADMA also reaffirmed its guidance for over $500 million in 2025 revenues and over $625 million by 2026. Its long-term goal remains at over $1.1 billion in sales pre-2030.
zacks.com
ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.
See all news
